Il numero di luglio 2025 della rivista è online.
Di seguito le scelte dell’Editor che saranno scaricabili gratuitamente per i prossimi tre mesi:
Daniela Pugliese et al. Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study
D. Noviello et al. Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)
Emilie Toft Skovgaard et al. The heterogeneity of cirrhosis - systemically assessed endotypes described by fibrosis, apoptosis, and immunoregulatory-related biomarkers
Jung-Bin Park et al. Risk factors for residual tumors in histologically incompletely resected rectal neuroendocrine tumors